Survival gain with new drugs;Guadagno di sopravvivenza dei nuovi farmaci

PharmacoEconomics - Italian Research Articles

Volumn 6, Issue 2, 2004, Pages 95-104

  Messori, Andrea ^a,b   Santarlasci, B ^a   Trippoli, S ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Centro di Informazione sul Farmaco   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; IRINOTECAN; LEVAMISOLE; MITOXANTRONE; NAVELBINE; NEW DRUG; PACLITAXEL; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RETINOIC ACID; RITUXIMAB; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; BREAST TUMOR; CALCULATION; CANCER SURVIVAL; CLINICAL STUDY; COLON CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ESOPHAGUS CANCER; HEALTH CARE COST; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LUNG TUMOR; MEDICAL LITERATURE; MEDLINE; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PANCREAS CANCER; PROMYELOCYTIC LEUKEMIA; PUBLICATION; REVIEW; SEPSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL PARAMETERS; SURVIVAL RATE;

EID: 2942635095     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320627     Document Type: Review

References (37)

1. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data on outcomes. N Engl J Med 1998; 339: 380-6
2. Messori A, Becagli P, Trippoli S. Median versus mean lifetime survival in the analysis of survival data. Haematologica 1997; 82 (6): 730
3. Messori A, Trippoli S, Vaiani M. Cost-effectiveness of innovative anti-cancer drugs (Letter). eBMJ, 5 August 2002, web address: http://bmj.com/cgi/eletters/325/7358/269#24426
4. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-25
5. Messori A. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol 1998; 9 (4): 389-96
6. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100 (13): 4298-302
7. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19 (3): 602-11
8. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcoma of the extremities and girdles; results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19: 1238-47
9. Hancock BW, Gregory WM, Cullen MH, et al.; British National Lymphoma Investigation; Central Lymphoma Group. ChIVPP alternating with PABIOE is superior to PABIOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer 2001; 84 (10): 1293-300
10. Mainwaring PN, Cunningham D, Gregory W, et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 2001; 97 (10): 2991-7
11. Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001; 48: 1685-91
12. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346 (4): 235-42
13. Lygidakis NJ, Sgourakis G, Giorgia D, et al. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease. Ann Surg 2002; 236: 806-13
14. Taal BG, Van Tinteren H, Zoetmulder FA; NACCP group. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85 (10): 1437-43
15. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22
16. Porschen R, Bermann A, Loffler T, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCa-01. J Clin Oncol 2001; 19: 1787-94
17. List AF, Kopecky JK, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212-20
18. Kim TY, Yang SH, Lee SH, et al. A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J clin Oncol 2002; 25 (3): 238-43
19. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first line therapy for women with metastatic breast cancer: final results of a randomized phase III muticenter trial. J Clin Oncol 2001; 19: 1707-15
20. Jelic S, Stamatovic Lj, Vucicevic S, et al. Use of high-dose cytarabine to enhance cisplatin cytotoxicity effects on the response and overall survival rates of advanced head and neck cancer patients. Eur J Cancer 2002; 38: 1478-89
21. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92
22. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-33
23. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002; 346: 85-91
24. Comella P. Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer. Semin Oncol 2001; 28: 7-10
25. O'Shaughnessy J, Miles D, Vukelia S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-23
26. Gansauge F, Ramadani M, Pressmar J, et al. NSC-631570(Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbeck's Arch Surg 2002; 386: 570-4
27. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group phase III trial. Lung Cancer 2001; 34 (Suppl. 4): S65-9
28. Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil for metastatic colorectal cancer: a new survival standard. Oncologist 2001; 6: 81-91
29. Liu Yin JA, Wheatley K, Rees JK, Burnett AK; UK MRC Adult Leukemia Working Party. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113 (3): 713-26
30. Jelic S, Mitrovic, L, Radosavljevic D, et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer 2001; 34 (1): 1-13
31. Pujol JL, Daure JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4-epidoxorubicin plus cyclophosphamide in treatment of extensive small cell lung cancer: a French federation of cancer institutes multicenter Phase III randomized trial. J Natl Cancer Inst 2001; 93: 300-8
32. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19 (1): 10-7
33. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344 (10): 699-709
34. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347 (13): 993-1000
35. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock (SCHOCK trial). Indian Heart J 2001; 53 (2): 240
36. Sibbald B. Making a case for a $2700-a-month drug. CMAJ 1999;161 (9): 1173
37. Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: stato dell'arte della metodologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics-Italian Research Articles 2003;5:53-67